Document:

Offer Letter

 EXHIBIT 10.20 
 Confidential 
 July 14, 2011 

David N. Strohm 
 [Address] 

Dear David: 
 On behalf of Imperva, Inc. (the
“Company”), I am pleased to inform you that the Company’s Board of Directors (the “Board”) is interested in having you serve as a member of the Board and as a member of the Board’s Audit Committee. If all
necessary Board and stockholder action is taken, the Company is prepared to offer you the compensation described below in exchange for your performance of certain duties as a director.  

If elected as a member of the Board, you will be offered the opportunity to purchase 100,000 of Company’s Common Stock under the Company’s
Stock Option Plan (the “Initial Shares”), as amended from time to time (the “Plan”), a copy of which will be furnished to you. We expect that you will be appointed to the Board at the Board meeting to be held on
August 17, 2011 and at this meeting the purchase of the Initial Shares would be approved by the Board. The Initial Shares shall vest as follows: 25% of the Initial Shares shall vest after 12 months of service on the Board and the remainder of
the Initial Shares shall vest in 36 equal monthly installments as you continue service on the Board. Such vesting shall commence as of your election to the Board. The vesting of your Initial Shares shall accelerate fully upon a change of control of
the Company pursuant to and in accordance with the terms of the Plan. In addition, you will be offered the opportunity to purchase an additional 50,000 shares of the Company’s Common Stock in connection with the Company’s proposed initial
public offering (the “Subsequent Shares”). The Subsequent Shares shall not be subject to vesting. Finally, in connection with the Company’s proposed initial public offering, the Company intends to implement a compensation
policy for members of the Board and you will participate in the program we implement. 
 For so long as you are a member of the Board, the
Company will reimburse you for your reasonable out-of-pocket expenses, including reasonable travel expenses, incurred in attending Company Board meetings and committee meetings and in carrying out your duties as a director or committee member.

 You understand that, if elected, you will serve on the Board at the pleasure of the stockholders of Company. You know of no reason why you
would be precluded from serving as a member of the Board or any of its committees, either because of existing competition restrictions or fiduciary duty obligations or otherwise. 
 On behalf of the Company, we are excited about the possibility of having you join us at this critical juncture in our growth and development. 

 

	
	Sincerely,
	
	
	Shlomo Kramer,
	Chief Executive Officer

 Acknowledged and agreed to on 
 this 14th day of July, 2011 
  

	
	/s/ David N. Strohm
	David N. StrohmOffer Letter

 EXHIBIT 10.21 
 Confidential 
 July 20, 2011 

Frank Slootman 
 [Address] 

Dear Frank: 
 On behalf of Imperva, Inc. (the
“Company”), I am pleased to inform you that the Company’s Board of Directors (the “Board”) is interested in having you serve as a member of the Board and as a member of the Board’s Compensation Committee.
If all necessary Board and stockholder action is taken, the Company is prepared to offer you the compensation described below in exchange for your performance of certain duties as a director.  

If elected as a member of the Board, you will be offered the opportunity to purchase 80,000 of Company’s Common Stock under the Company’s Stock
Option Plan (the “Initial Shares”), as amended from time to time (the “Plan”), a copy of which will be furnished to you. We expect that you will be appointed to the Board at the Board meeting to be held on
August 17, 2011 and at this meeting the purchase of the Initial Shares would be approved by the Board. The Initial Shares shall vest as follows: 25% of the Initial Shares shall vest after 12 months of service on the Board and the remainder of
the Initial Shares shall vest in 36 equal monthly installments as you continue service on the Board. Such vesting shall commence as of your election to the Board. The vesting of your Initial Shares shall accelerate fully upon a change of control of
the Company pursuant to and in accordance with the terms of the Plan. In addition, you will be offered the opportunity to purchase an additional 50,000 shares of the Company’s Common Stock in connection with the Company’s proposed initial
public offering (the “Subsequent Shares”). The Subsequent Shares shall not be subject to vesting. Finally, in connection with the Company’s proposed initial public offering, the Company intends to implement a compensation
policy for members of the Board and you will participate in the program we implement. 
 For so long as you are a member of the Board, the
Company will reimburse you for your reasonable out-of-pocket expenses, including reasonable travel expenses, incurred in attending Company Board meetings and committee meetings and in carrying out your duties as a director or committee member.

 You understand that, if elected, you will serve on the Board at the pleasure of the stockholders of Company. You know of no reason why you
would be precluded from serving as a member of the Board or any of its committees, either because of existing competition restrictions or fiduciary duty obligations or otherwise. 
 On behalf of the Company, we are excited about the possibility of having you join us at this critical juncture in our growth and development. 

 

	
	Sincerely,
	
	
	Shlomo Kramer,
	Chief Executive Officer

 Acknowledged and agreed to on 
 this 20th day of July, 2011 
  

	
	/s/ Frank Slootman
	Frank SlootmanAmendment No 2 to the Series A and Series A-1 Preferred Stock Purchase Agreement

 EXHIBIT 10.22 
 INCAPSULA, INC. 
 AMENDMENT NO. 2 TO THE 

SERIES A AND SERIES A-1 PREFERRED STOCK PURCHASE AGREEMENT 

THIS AMENDMENT NO. 2 TO THE SERIES A AND SERIES A-1 PREFERRED STOCK PURCHASE AGREEMENT (the
“Amendment”) is made by and among Incapsula, Inc., a Delaware corporation (the “Company”), and the undersigned investor of the Company (the “Investor”), as of this 24th day of October, 2011. 

RECITALS 
 WHEREAS, the Company and the Investor are parties to that certain Series A and Series A-1 Preferred Stock Purchase Agreement, dated March 9, 2010, (the “Purchase Agreement”);

 WHEREAS, the Company and Investor previously entered into that certain Amendment No. 1 to the Series A and
Series A-l Preferred Stock Purchase Agreement on December 31, 2010; and 
 WHEREAS, the Company and
Investor now desire to further amend the timing for the sale, if any, of Series A-l Preferred Stock; and 

WHEREAS, the Investor holds a majority of the Conversion Shares (as defined in the Purchase Agreement) issued or issuable
upon conversion of the Shares purchased pursuant to the Purchase Agreement, and the consent of such holders will bind all parties to the Purchase Agreement pursuant to Section 6.9 thereof. 

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS: 

 

	 	1.	 Amendments to the Purchase Agreement 

 (a)        Pursuant to Section 6.9 of the Purchase Agreement, Section 1.3 of the Purchase Agreement is hereby amended and restated in its entirety to read
as follows: 
 “1.3 Subsequent Sale of Series A-1 Preferred Stock.  If
within eighteen (18) months of the Closing, the Company achieves those certain milestones as set forth on Exhibit B hereto (the “Milestones”), and the Chief Executive Officer of the Company certifies in writing to each investor
that the Milestones have been achieved (the “Company CEO Certification”), then, subject to the terms and conditions of this Agreement including the provisions contained in the following paragraphs, each Investor will purchase and
the Company will sell and issue at a “First” subsequent closing and a “Second” subsequent closing (each, a “Subsequent Closing”) that number of Series A-l Shares set forth opposite such Invstor’s name on
Schedule B hereto for $0.80 per share. 

 First Subsequent Closing (if any):  The
First Subsequent Closing will occur in two tranches as follows: (1) the first tranche of the First Subsequent Closing shall occur within seven (7) days of the receipt by each Investor of the Company CEO Certification; and (2) the second tranche
of the First Subsequent Closing shall occur on or before September 30, 2011 with the specific closing date to be mutually agreed upon by the Company and Investor. 

Second Subsequent Closing (if any):  The Second Subsequent Closing will be on or before
March 31, 2012 with the specific closing date to be mutually agreed upon by the Company and Investor. 
 Any Series A-1 Shares sold pursuant to this Section 1.3 shall be deemed “Shares” for all purposes under this Agreement and any purchasers thereof shall be deemed to be an
“Investor” under this Agreement and each of the Ancillary Agreements (as defined below) and any amendment thereof. Where appropriate, “Closing” shall be deemed to include a “Subsequent Closing” or any tranche thereof.
Subject to the provisions contained in the following paragraph, the purchase and sale of the Series A-1 Shares shall take place at the Menlo Park, CA offices of Goodwin Proctor LLP, or at such other place as the Company and the
Investor agree upon orally or in writing. At the Subsequent Closing or any tranche thereof, the Company shall deliver to each Investor a certificate representing the Series A-1 Shares that such Investor is purchasing pursuant to this Agreement
against payment of the purchase price therefor by check or wire transfer, or any combination thereof. 
 Notwithstanding the foregoing, the board of directors of Imperva, Inc. (the “Imperva Board”) may conduct an audit of the Company’s achievement of the Milestones during a period of
fourteen (14) days following receipt of the Company CEO Certification. In connection with such audit, the Company will provide the Imperva Board with reasonable access to the Company’s books and records as is necessary for the Imperva
Board to determine whether the Milestones have been achieved. In the event that the Imperva Board concludes that any of the Milestones have not been achieved, then the Imperva Board shall submit to the Company a certification in writing specifying
which Milestones have not been met and suggest three (3) potential independent third parties to arbitrate the dispute regarding completion of the Milestones (the “Imperva Board Certification”). Such arbitrator shall not be an
officer, director, employee, consultant, family member, greater than live percent (5%) stockholder or direct competitor of either Imperva or the Company. Upon the Company’s receipt of the Imperva Board Certification, the Chief Executive
Officer of the Company shall select one of the proposed arbitrators to conduct an audit to determine whether or not the Milestone(s) in question have been achieved by the Company. The Chief Executive Officer of the Company shall provide advance
notice in writing 

 
to the Imperva Board with the name of the arbitrator selected and the date the arbitrator’s audit is to commence. Prior to the commencement of the of the arbitrator’s audit, the
arbitrator shall enter into a nondisclosure agreement, the form of which is reasonably acceptable to the Company. The arbitrator’s audit shall be completed within twenty-eight (28) days from the commencement date of the arbitrator’s
audit. If the arbitrator determines that the Milestones in question were achieved, Imperva will bear all reasonable costs and expenses incurred by the arbitrator related to the audit, If, however, the arbitrator determines that the Milestones in
question were not achieved, all reasonable costs and expenses incurred by the arbitrator in connection with the audit will be shared by the Company.” 
 (b)        Pursuant to Section 6.9 of the Purchase Agreement, Schedule B of the Purchase Agreement is hereby amended and restated in its entirety to read
as follows: 
 Schedule B 
 Schedule of Investors (Series A-l Preferred Stock) 
   First Subsequent
Closing (Tranche #1) 
  

					
	Investor Name & 
Address	 	Number of Shares of Series
A-1 Preferred Stock	 	Total Purchase Price 
of
Series A-1 Preferred Stock
	 Imperva, Inc.

3400 Bridge Parkway, Suites 200 Redwood City, CA 94065
	 	625,000	 	$500,000

   First Subsequent Closing (Tranche #2) 

 

					
	Investor Name & 
Address	 	Number of Shares of Series
A-1 Preferred Stock	 	Total Purchase Price 
of
Series A-1 Preferred Stock
	 Imperva,
Inc. 3400 Bridge Parkway, Suites 200 Redwood City, CA 94065
	 	3,750,000	 	$3,000,000

   Second Subsequent Closing 

 

					
	Investor Name & 
Address	 	Number of Shares of Series
A-1 Preferred Stock	 	Total Purchase Price 
of
Series A-1 Preferred Stock
	 Imperva,
Inc. 3400 Bridge Parkway, Suites 200 Redwood City, CA 94065
	 	4,375,000	 	$3,500,000

2.            Continued Validity of Purchase
Agreement.  Except as amended hereby, the Purchase Agreement shall continue in full force and effect as originally constituted and is ratified and affirmed by the parties hereto. 

3.            Successors and
Assigns.  Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. 

4.            Governing Law.  This
Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California. 

5.            Counterparts.  This Agreement
may be executed in two or more-counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have executed this Amendment No. 2 to the Series A and Series A-l Preferred Stock Purchase Agreement as of the date first above written. 

 
  

			
	 COMPANY

	
	 By:/s/ Gur
Shatz                                        

	
	 Name: Gur Shatz

	
	 Title:   CEO & President

	
	 IMPERVA, INC.

	
	 By:/s/ Shlomo
Kramer                                

	
	 Name: Shlomo Kramer

	
	 Title:   President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]